Table 1.
The biocompatible polymer-based cancer theranostics.
| Imaging Modality | Polymers | Imaging Agents | Encapsulated Moiety | Targeting Moiety | Refs |
|---|---|---|---|---|---|
| MRI | Poly(trimethylene carbonate)–poly(L-glutamic acid) (PTMC-b-PGA copolymer) | Ultrasmall superparamagnetic iron oxides (USPIOs) | Doxorubicin | [51] | |
| MRI | PTMC-b-PGA copolymer | USPIOs | Doxorubicin | HER-2 | [52] |
| MRI | Poly(acrylic acid-co distearin acrylate) | Superparamagnetic iron oxide nanoparticles (SPIONs) | Doxorubicin | Folic acid | [53] |
| MRI | PluronicR L-121 (EO5-PO68-EO5) | SPIONs | Camptothecin | Bombesin | [54] |
| MRI | PTMC b-PGA copolymer | USPIO’s | Doxorubicin | [55] | |
| MRI | (FA or methoxy)-PEG114–P (Glu-Hyd-DOX)-PEG–acrylate46 SPIO | Superparamagnetic iron oxides (SPIO) | Doxorubicin | Folic acid | [56,57] |
| MRI | PEO–PLGA–PEO (polyethylene oxide–poly D,L lactide-co-glycolide–polyethylene oxide) | Iron oxide (Fe3O4) | Doxorubicin | [58] | |
| MRI | methoxy or folate (FA)-PEG 114–PLA-PEG-acrylate 46 SPIO NPs | SPIO NPs | Doxorubicin | Folic acid | [56,57] |
| Ultrasound | PLGA (poly(D,L-lactide-coglycolide)) | Fe3O4 | H2O2 | [59] | |
| Ultrasound Optical imaging | Poly(ethylene glycol)-bpoly(L-aspartic acid) (PEG-PAsp) | - | Doxorubicin Calcium carbonate | Rabies virus glycoprotein (RVG) peptide | [60] |
| Optical imaging | PLGA | Mercaptosuccinic acid( MSA)-coated CdTe QDs | Doxorubicin | [61,62] | |
| Optical imaging | poly(2-hydroxyethyl-cooctadecyl aspartamide) (PHEA-C18) | Magnetic resonance tomography (MIR) fluorescent probe, FPR-675 | Folic acid | [63] | |
| Optical imaging | poly(ethylene glycol)-copoly(trimethylene carbonate-cocaprolactone) | Multiporphyrin near-infrared (NIR) fluorophores | [64] | ||
| Optical imaging | PPF–PLGA–PEG polymer | Rhodamine B | Folic acid | [65] | |
| Optical imaging | PPF–PLGA–PEG copolymer | - | Doxorubicin | [66] | |
| Optical imaging | Polytyrosine | - | Doxorubicin | [67] | |
| Optical imaging | Polyethylenimine | Hematoporphyrin | - | [68] |